Table 2.
Pattern characteristics by age group (on-line only).
| Patient characteristics | Age Croup (years) |
Total | |||
|---|---|---|---|---|---|
| <60 |
60–69 |
≥70 |
|||
| n(%) | n(%) | n(%) | |||
|
| |||||
| Study Regimen | CTP- > Placebo | 307 (32.8) | 214 (35.1) | 104 (31.7) | 625 |
| CTB- > Placebo | 307 (32.8) | 201 (33.0) | 117 (35.7) | 625 | |
| CIB- > Bevacmrnub | 321 (34.3) | 195 (32.0) | 107 (32.6) | 623 | |
| Performance status | 0 | 504 (53.9) | 296 (48.5) | 131 (39.9) | 931 |
| 1 | 381 (407) | 263 (43.1) | 165 (50.3) | 809 | |
| 2 | 50 (5.3) | 51 (8.4) | 32 (9.8) | 133 | |
| Primary site | Ovary | 835 (89.3) | 477 (78.2) | 251 (76.5) | 1563 |
| Fallopian tube | 16 (1.7) | 15 (2.5) | 5 (1.5) | 36 | |
| Primary peritoneum | 84 (9.0) | 118 (19.3) | 72 (22.0) | 274 | |
| Histologic type | Papillary serous | 760 (81.3) | 528 (86.6) | 297 (90.5) | 1585 |
| Endometrioid | 35 (3.7) | 17 (2.8) | 7 (2.1) | 59 | |
| Clear cell | 37 (4.0) | 15 (2.5) | 3 (0.9) | 55 | |
| Mucinous | 12 (1.3) | 6 (1.0) | 1 (0.3) | 19 | |
| Transitional | 16 (1.7) | 0 (0.0) | 0 (0.0) | 16 | |
| Other | 75 (8.0) | 44 (7.2) | 20 (6.1) | 139 | |
| Total | 935 | 610 | 328 | 1873 | |
The treatment regimens were carboplatin, paclitaxel and placebo for cycles 1–6 followed by placebo for cycles 7–22 (CTP->Placebo); carboplatin, paclitaxel for cycles 1-6 and bevacizumab for cycles 2–6 followed by placebo for cycles 7–22 (CTB->Placebo); carboplatin, paclitaxel for cycles 1–6 and bevacizumab for cycles 2–6 followed by bevacizumab for cycles 7–22 (CTB->Bevacizumab).